Johnson & Johnson Shares Hit 52-Week High as 2026 Revenue Outlook Tops $100 Billion
Johnson & Johnson shares hit a 52-week high after the company reported 2025 revenue of $94.19 billion and forecast 2026 revenue above $100 billion. The company also filed a shelf registration and said Innovative Medicine growth offset pressure from Stelara.
Johnson & Johnson shares reached a fresh 52-week peak of $242.36 after the company published its 2025 annual report and submitted a shelf registration to the U.S. Securities and Exchange Commission. Management forecast FY2026 revenue of $100.0 billion to $101.0 billion, with one outlook citing growth to approximately $101.54 billion.
The recently published annual report for 2025 showed annual revenue of $94.19 billion, EBIT of $32.81 billion, and net income of $26.8 billion. Guidance for FY2026 indicated year-over-year revenue growth of 6.2% to 7.2%, marking an acceleration from the growth rate observed in FY2025.
In Innovative Medicine, operational sales growth surged to 7.9% in Q4 2025, counterbalancing a negative impact of 1,110 basis points from Stelara. Key growth drivers reported strong results: Darzalex sales increased by approximately 20% year over year, Carvykti sales nearly doubled, and Tremfya grew around 17% year over year in 2024. Management has identified more than 10 potential assets in the pipeline, each with peak sales potential exceeding $5 billion.
The company said the shelf registration, filed on Form S-3ASR, provides future flexibility to issue new debt securities swiftly. Proceeds would be allocated for general corporate purposes, which could include funding investments, bolstering working capital, facilitating share repurchases, or financing potential acquisitions.
Johnson & Johnson said it has raised its dividend for 63 consecutive years, maintaining Dividend King status. The upcoming quarterly distribution is set at $1.30 per share, with an ex-dividend date of February 24 and payment scheduled for March 10.
The company said it operates through Innovative Medicine and MedTech. The MedTech segment includes products used in cardiovascular, orthopedics, surgery, and vision, while future plans cited in one source said Johnson & Johnson plans to spin off its orthopedics business in 2027, focusing medical device operations on cardiovascular, surgical, and vision sectors.
The annual report also outlined risks facing the business. Stelara faces pressure from emerging biosimilar competition, while the company continues to navigate talcum powder litigation and evolving U.S. regulations concerning drug pricing. Even so, the shares have rallied about 53% to 55% over the past twelve months and were trading near their 52-week high.